Turn the patent cliff into an annuity.
Every drug patent cliff strategy buys time. Only one converts a prescription that expires at loss of exclusivity into recurring consumer revenue the brand owns outright: the nonprescription switch, now open to chronic conditions under ACNU.
The Cliff
More revenue is going off patent than ever before.
A patent cliff is not a surprise. The date is known years in advance, the litigation calendar is public, and the generic and biosimilar makers are already tooling up. For a small molecule, most of the volume leaves the brand within the first year. Biologics erode more slowly, but they erode. Several of the best-selling drugs in the world lose U.S. exclusivity in the same three-year window, and every company is pulling the same levers at once: reformulate, contract, acquire. All of them slow the erosion. None of them replaces the revenue.
$200B+
Annual U.S. branded revenue facing loss of exclusivity by 2030
80%
Of a small-molecule brand's volume that can move to generics within a year
12 wks
From go decision to an actual use study on our ACNU platform
The next cliff, year by year
Brands losing U.S. exclusivity from 2028 on that already grade well on the ACNU Feasibility Leaderboard. Every one of them is a subscription waiting to be opened.
2028
Xifaxan
rifaximin
Small molecule
2029
Repatha
evolocumab
Biologic
2030
Trelegy Ellipta
fluticasone/
Small moleculeumeclidinium/ vilanterol
2031
Dupixent
dupilumab
BiologicDescovy
emtricitabine/
Small moleculetenofovir alafenamide Aimovig
erenumab
Biologic
2032
2033
Emgality
galcanezumab
BiologicNurtec ODT
rimegepant
Small molecule
2034
2035
Ubrelvy
ubrogepant
Small molecule
2028
Xifaxan
rifaximin
Small molecule
2029
Repatha
evolocumab
Biologic
2030
Trelegy Ellipta
fluticasone/
Small moleculeumeclidinium/ vilanterol
2031
Dupixent
dupilumab
BiologicDescovy
emtricitabine/
Small moleculetenofovir alafenamide Aimovig
erenumab
Biologic
2033
Emgality
galcanezumab
BiologicNurtec ODT
rimegepant
Small molecule
2035
Ubrelvy
ubrogepant
Small molecule
U.S. loss of exclusivity as publicly reported or expected. Actual generic or biosimilar entry depends on patent litigation, settlements, and regulatory exclusivities, and dates move. Letter grades are the brand’s ACNU feasibility grade on the Idea Evolver leaderboard as of September 2026; the leaderboard is refreshed, this snapshot is not.
The Strategies
Five strategies slow the erosion. One replaces the revenue.
Most lifecycle plans use three or four of these. Each one has a ceiling, and only one swaps a prescription that expires for a subscription that renews.
New formulations and delivery
Extended-release versions, new dosage forms, fixed-dose combinations, and auto-injectors that earn new patents on how the molecule is delivered.
- Best when
- The change gives patients something they can feel: fewer doses, easier administration, better tolerability.
- The ceiling
- Payers and prescribers see through cosmetic changes, and the original generic still arrives on schedule.
New indications and populations
Label expansions, pediatric studies, and new patient populations that extend the brand's reach and can add regulatory exclusivity.
- Best when
- The science supports a real second act and the trials can read out before the cliff.
- The ceiling
- Exclusivity gained this way is measured in months, or protects only the new indication while generics carve it out of their label.
Authorized generics and biosimilar deals
License the molecule to a generic or biosimilar partner, or launch one yourself, to keep a share of the volume that leaves the brand.
- Best when
- The brand cannot hold price and would rather own a slice of the commodity market than none of it.
- The ceiling
- The margin is thin by design. This preserves some revenue but not the franchise.
Pricing, contracting, and patient support
Defend formulary position with net price, rebates, copay programs, and adherence support that make leaving the brand a hassle for the patient.
- Best when
- The brand has a differentiated experience and a loyal prescriber base worth paying to keep.
- The ceiling
- Contracting slows the slide. It has never stopped one, and it compresses margin every year it runs.
Portfolio replacement
Acquire or in-license the next asset so the company's revenue line survives the brand's decline.
- Best when
- Balance sheet and pipeline gaps line up, and the target can be integrated before the cliff hits.
- The ceiling
- The most expensive lever, and the one that does nothing for the brand itself.
- The annuity
Rx-to-OTC switch, now including ACNU
Move the molecule into a nonprescription franchise the brand owns outright. Consumers qualify, buy, and refill through the brand, so a chronic-condition prescription becomes a subscription that renews instead of a revenue line that ends at loss of exclusivity.
- Best when
- The condition is common and long-term, the safety profile is acceptable, and consumers can self-select correctly, from a label or with technology assistance.
- The ceiling
- Historically limited to drugs consumers could self-select from a box. ACNU removes that ceiling for chronic conditions, where the recurring revenue is.
The Switch Play
Stop competing with the generic. Sell the subscription instead.
When a prescription brand goes generic, the pharmacy substitutes it. The prescriber rarely notices, the patient never sees the box, and the brand competes on net price against a commodity.
A nonprescription switch moves the molecule into a market that works the other way around: the consumer picks the name they know. Prilosec OTC, Claritin, Allegra, Nexium 24HR, and Flonase each made this move after prescription exclusivity ended, and each is still a consumer franchise today.
An ACNU switch goes one step further. The self-selection app is also the storefront: the consumer qualifies, checks out, and refills through the brand, month after month, for a condition they will treat for years. That is an annuity, billed directly, with no pharmacy substitution and no rebate in between.
The moat
A switch supported by new clinical investigations can also earn up to three years of marketing exclusivity, and the subscriber base and self-selection technology behind an ACNU switch are not something a generic can copy from the label.
Why It Was Off the Table
Most molecules could never switch. ACNU changed the rule.
A traditional switch requires that a consumer can read a Drug Facts label and decide correctly on their own. Statins fell short of that bar at FDA advisory committees more than once, and most other chronic-condition drugs, where the revenue on this cliff sits, never came close. FDA’s Additional Condition for Nonprescription Use rule lets a product require a technology-assisted step before purchase. In AstraZeneca’s Technology-Assisted Cholesterol Trial in Consumers (TACTiC), our device showed consumers could safely self-select, acquire, and use a statin over six months with that step in place.
| Traditional switch | ACNU switch | |
|---|---|---|
| How consumers self-select | Reading the Drug Facts label on the package. | A technology-assisted questionnaire or app that must be completed before purchase. |
| What the product can require | Nothing beyond the label itself. If a warning cannot fit on a box, the drug cannot switch. | An additional condition: screening questions, a lab value, or a clinician-style decision path built into software. |
| Which molecules qualify | Conditions consumers can diagnose and treat on their own: allergy, heartburn, pain, smoking cessation. | Chronic conditions with clear eligibility rules: cholesterol, hypertension, contraception, migraine prevention, and more. |
| How the revenue arrives | Retail unit sales through the trade, one box at a time, with no view of who bought it. | Direct-to-consumer subscriptions the brand bills and refills itself, with the subscriber relationship on its own books. |
| What the brand protects | A consumer brand and shelf presence built on the Rx name. | The same, plus a subscriber base and first-mover self-selection technology generics cannot copy from the label. |
Timing
An annuity pays whenever it starts. It pays most when it starts on the cliff.
Every year a generic has the market to itself is a year of subscribers the brand never signs. Feasibility takes weeks. The studies and FDA review take the rest of the runway.
Feasibility
24 to 36 months before loss of exclusivity
Score unmet need, safety profile, and market size. Decide whether the molecule is a switch candidate before committing study budget.
Build and pre-studies
Within 6 to 8 weeks of a go decision
Build the self-selection technology, complete SaMD (software as a medical device) validation, and run label comprehension and self-selection studies.
Actual use study
Within 12 weeks of a go decision
Show FDA that real consumers can select, buy, and use the drug safely over time without a practitioner in the loop.
Submission and launch
Timed to the cliff
File the application, stand up checkout, fulfillment, and refills, and start signing subscribers as the Rx exclusivity ends, while the brand name still owns the category.
Feasibility
Is your molecule an annuity candidate?
We score every major brand and condition on the three questions a switch program has to answer first. The answers are public on the ACNU Feasibility Leaderboard.
- Is there sufficient unmet need?
- Is the safety profile acceptable?
- What is the potential market size?
What is a drug patent cliff?
A patent cliff is the sharp drop in a branded drug's revenue after its patents and regulatory exclusivities expire and generic or biosimilar competitors enter the market. For small molecules, most of the volume can move to generics within the first year. Biologics erode more slowly, but the direction is the same.
How much revenue is at risk in the current patent cliff?
Industry analysts estimate that more than $200 billion in annual branded drug revenue faces loss of exclusivity in the United States by 2030, the largest wave the industry has seen, and the losses keep coming through the mid-2030s. Several of the best-selling drugs in the world are expected to lose U.S. exclusivity in 2028 alone.
Why is an Rx-to-OTC switch a patent cliff strategy?
When a prescription drug goes generic, the brand competes on price against a commodity. When the brand switches the molecule to nonprescription status, it enters a market where the brand name is the asset and consumers buy it by name. Switches supported by new clinical investigations can also earn up to three years of marketing exclusivity. Prilosec OTC, Claritin, Allegra, and Flonase all followed this path after their prescription exclusivity ended.
What does it mean to turn a patent cliff into a subscription annuity?
A chronic-condition drug is taken every day for years. Under ACNU the consumer qualifies, buys, and refills through the brand's own self-selection app, so the revenue arrives as a recurring direct-to-consumer subscription the brand bills itself, rather than as a prescription a pharmacy substitutes the day the generic arrives. The brand keeps the customer relationship, the pricing, and the renewal.
What does ACNU change about the switch strategy?
ACNU, FDA's Additional Condition for Nonprescription Use rule, lets a nonprescription drug require a condition beyond the label, such as a technology-assisted self-selection questionnaire, before purchase. That opens the switch to chronic-condition drugs that could never fit their eligibility rules on a box, which is exactly where most of the revenue going off patent lives. Because the condition lives in software, the same app can handle checkout and refills, which is what makes the switch a subscription rather than a one-time retail sale.
When should a brand start planning a switch?
Two to three years before loss of exclusivity. Feasibility can be assessed in weeks, but the self-selection technology, validation studies, actual use study, and FDA review take time. A later switch still pays. A subscription that opens as the Rx exclusivity ends inherits the brand's full recognition and signs subscribers while the name still owns the category, instead of rebuilding that position years later.
Connect With Us
Turn your patent cliff into an annuity.
Whether the opportunity begins with visibility or nonprescription access, we’ll help you find the clearest next move across Search, AI and ACNU.
contact@idea-evolver.com